Ascidian Therapeutics

With the business year almost complete, a review of biopharmaceutical dealmaking showed that Novartis, in particular, enjoyed a very productive year with 21 transactions overall, including six acquisi

Roche is to collaborate with Ascidian Therapeutics to discover and develop novel RNA exon editing therapeutics targeting neurological diseases, in a deal that could be worth up to $1.8bn. The Bosto

October ended and November began with the announcement of three new venture capital and equity funds with more than $1.3bn for health care, life science and biopharmaceutical investments. Revelation P